IBA - Bright future to start as from H2-24
Bright future starts as of H2 246 PT systems are foreseen to be installed/shipped in H2e, resulting in a H2e REBIT of EUR 17m. We consider this as a reassuring indication of where future profitability could go if they manage to convert the backlog.Progress is foreseen to continue in 2024e, although we do not expect a revamping year yet. The bulk of the revenues from the 10 Spanish PT systems is expected in 2025e meanwhile Other Accelerators (AO) is only foreseen to improve as of Q3 24e. FY24e REBIT is therefore only expected at EUR 9.7m.Improvement in profitability set toIBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.